anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study is a prospective, randomized, non-blinded, single-center Phase Ib trial. Patients will be identified that have a diagnosis of breast or ovarian cancer, have completed their standard courses of therapy and are disease-free. They will be properly screened, counseled and consented prior to enrollment. Once enrolled, each patient's blood will be tested for HLA-A2 status (approximately 50% will be HLA-A2+). Additionally, their tumors will be tested for FBP-expression and this information will be tracked for purposes of correlative science.

Patients who are HLA-A2+ will be stratified based on cancer diagnosis (breast versus ovarian), then randomized by computer tables to one of three arms for the PVS. Each arm will receive 6 monthly injections of peptide + GM-CSF. Arm A will receive six inoculations with E39 peptide; arm B will receive three inoculations with E39 followed by three with J65; and arm C will receive three inoculations with J65, followed by three of E39. Since J65 has not been previously used in humans, a two week waiting period will be instituted between the first and second patients enrolled in either Arm B or C. Immunologic data will be assessed at 1 month and 6 months (±2 wks) after the PVS, specifically ex vivo immunologic recognition of E39 and J65 will be assessed by clonal expansion using a dextramer assay and the in vivo response will be assessed by Delayed Type Hypersensitivity (DTH). Immunologic recognition of E39 will be the primary endpoint, with recognition of J65 serving as an additional data point. The 6 month post-PVS immunologic data will then be used to assess each patient for significant residual immunity (SRI), defined as ≥2-fold increase in E39-specific CD8+ T-cells from the pre-vaccination level. Patients will then be sorted into two groups: those with SRI and those without. Patients within each group will then be randomized to receive one booster of either J65 or E39. Each patient will return to clinic within 1-2 weeks of their 6mo post-PVS visit to receive their single booster inoculation. This second randomization will result in four groups: 1) patients with SRI receiving E39; 2) patients with SRI receiving J65; 3) patients without SRI receiving E39; 4) patients without SRI receiving J65. Immunologic data will then again be gathered at 1 month (±2 wks) and 6 months (±2 wks) post-booster. This final immunologic data will be analyzed for differences between the four groups. Additionally, toxicity data will be gathered.

Patients will be monitored closely for one hour after each inoculation with questioning, serial exams, and vital signs every 15 minutes. Patients will then be asked to return to the vaccine clinic 48-72 hours after each inoculation for questioning regarding any local or systemic toxicity and to examine and measure the local reaction at the vaccination sites. The graded toxicity scale (NCI Common Terminology Criteria for Adverse Events, v4.03) will be utilized to assess local and systemic toxicity. GM-CSF dose reduction may be required if \>10cm of erythema and induration is seen at the injection site after any given inoculation.
PURPOSE: A target therapeutic agent of cancer stem cells using berberine is provided to suppress the expression of drug resistance target factor and induces apoptosis of cancer stem cells. CONSTITUTION: A target therapeutic agent of cancer stem cells contains berberine of chemical formula 1, its derivative or their pharmaceutically acceptable salt as an active ingredient. In chemical formula 1, X is halogen atom or sulfate. The cancer stem cell is breast cancer stem cells. The breast cancer cells express target factor of breast cancer stem cell, target factor of breast cancer resistance drug, target factor of breast cancer diagnostic receptor, target factor of epithelial cells, or target factor of neural cells. The breast cancer stem cell is deposit number KCLRF-BP-00137, KCLRF-BP-00138 or KCLRF-BP-00174. A food composition for preventing or treating cancer stem cells contains the berberine of chemical formula 1, its derivative or their salt as an active ingredient.
In past years, much research has been done into the beneficial effects of cytoreductive nephrectomy in patients with metastatic renal cancer receiving systemic therapy with positive results. In the meantime systhemic therapy, and in particular immunotherapy, have changed. Patients with metastatic renal cancer are increasingly treated with immunocheckpoint inhibitors, but the effect of adding cytoreductive nephrectomy in this group of patients has not yet been investigated. The aim of this study is to investigate whether performing a cytoreductive nephrectomy has a beneficial effect on overall survival in patients with metastatic renal cancer receiving systemic therapy using immunocheckpoint inhibitors.

A randomized controlled trial. All eligible patients have already been enrolled in the PRO-RCC registry, a registry that collects prospective observational data, and have also given consent to be included in other studies as a control cohort. This design is called a TWiC (trial within cohort). After randomization, patients who are randomized into the therapy arm will receive a patient information via their treating physician. Upon participation, an informed consent will be signed and the patient will be scheduled for surgery.
Although the newly developed biologics targeting IL-23/Th17 axis are highly effective in controlling psoriasis, all the biologics should be continuously injected to suppress recurrence of the disease. In this regard, the observation in our phase I psoriasis clinical trial was groundbreaking that just a single dose of anti-IL-23p19 antibody administration produced disease clearance up to 66 weeks in 46% (6 of 13) of patients. Since FoxP3 mRNA levels remained high in posttreatment biopsy specimens of these patients, we hypothesized that IL-23p19 inhibition increased regulatory T-cell levels or function in resolved psoriatic skin. However, there is a lack of understanding about regulatory immune cell promotion by IL-23p19 inhibition in human skin.

Our overall objectives of the study, are to (i) identify regulatory immune cell alterations induced by anti-IL-23p19 antibody administration in the skin of patients whose psoriasis is cleared without recurrence and (ii) develop pre-treatment predictive models for psoriasis patients that anticipate disease clearance and recurrence after short-term anti-IL-23p19 antibody injection. The rationale for this project is that molecular evidence of immune tolerance induction by IL-23p19 inhibition in human skin is likely to offer a strong clinical framework whereby new strategies to prevent recurrence of chronic inflammatory diseases can be developed. In this study, subjects with moderate-to-severe psoriasis will receive FDA-approved anti-IL-23p19 antibody (Generic name: Risankizumab, Product name: SKYRIZI™ or risankizumab-rzaa) up to 4 months following the FDA-approved indications, usage, dosage, and administration in the FDA-approved dosage forms and strengths through week 16, after which, dosing stops.
The proposed study will rigorously test the efficacy of an innovative, couplesbased HIV/STI risk reduction intervention to decrease new cases of HIV and Hepatitis C (HCV) and incidence of sexually transmitted infections (STIs), as well as to reduce unsafe injection practices and increase condom use among injecting drug users (IDUs) and their heterosexual intimate partners in Kazakhstan. Central Asia has experienced one of the fastest growing HIV/AIDS epidemics due to a sharp increase in injection drug use. For the proposed study, the participants will be 400 IDUs and their heterosexual intimate partners. These 400 couples will be randomized to one of two interventions: a 5session couplesbased HIV/STI risk reduction intervention or a 5session couplesbased wellness promotion intervention, which will serve as a control condition. Participants will be assessed with repeated measures at baseline, 3, 6, and 12months postintervention. The primary behavioral outcomes are selfreported proportion of injection acts in which needles or syringes are shared in the past 90 days and proportion of condom protected acts of sexual intercourse in the past 90 days. The primary biological outcomes are the rate of new HIV and HCV cases, and the cumulative incidence of Chlamydia, gonorrhea, and syphilis over the 12month postintervention period. The proposed study will advance the understanding of HIV/HCV/STI risk reduction among IDUs and thereby may help to stem the rising epidemic of HIV, HCV, and STIs in Kazakhstan and Central Asia.
BACKGROUND: Despite the availability of effective therapies for patients with chronic kidney disease, type 2 diabetes, and hypertension (the kidney-dysfunction triad), the results of large-scale trials examining the implementation of guideline-directed therapy to reduce the risk of death and complications in this population are lacking.
METHODS: In this open-label, cluster-randomized trial, we assigned 11,182 patients with the kidney-dysfunction triad who were being treated at 141 primary care clinics either to receive an intervention that used a personalized algorithm (based on the patient's electronic health record [EHR]) to identify patients and practice facilitators to assist providers in delivering guideline-based interventions or to receive usual care. The primary outcome was hospitalization for any cause at 1 year. Secondary outcomes included emergency department visits, readmissions, cardiovascular events, dialysis, and death.
RESULTS: We assigned 71 practices (enrolling 5690 patients) to the intervention group and 70 practices (enrolling 5492 patients) to the usual-care group. The hospitalization rate at 1 year was 20.7% (95% confidence interval [CI], 19.7 to 21.8) in the intervention group and 21.1% (95% CI, 20.1 to 22.2) in the usual-care group (between-group difference, 0.4 percentage points; P = 0.58). The risks of emergency department visits, readmissions, cardiovascular events, dialysis, or death from any cause were similar in the two groups. The risk of adverse events was also similar in the trial groups, except for acute kidney injury, which was observed in more patients in the intervention group (12.7% vs. 11.3%).
CONCLUSIONS: In this pragmatic trial involving patients with the triad of chronic kidney disease, type 2 diabetes, and hypertension, the use of an EHR-based algorithm and practice facilitators embedded in primary care clinics did not translate into reduced hospitalization at 1 year. (Funded by the National Institutes of Health and others; ICD-Pieces ClinicalTrials.gov number, NCT02587936.).
Chronic pain has emerged as a significant public health issue, seriously affecting patients' quality of life and psychological well-being, with a lack of effective pharmacological treatments. Numerous studies have indicated that macrophages play a crucial role in inflammatory pain, and targeting neuro-immune interactions for drug development may represent a promising direction for pain management. Chilobrachys jingzhao (C. jingzhao) is used as a folk medicine of the Li nationality with the efficacy of eliminating swelling, detoxicating, and relieving pain, and the related products are widely used in the market. However, the chemical constituents of C. jingzhao have not been reported, and the pharmacodynamic substance and the precise functional mechanism are unrevealed. Here we isolated a cyclic dipeptide, cyclo(L-Pro-L-Trp) (CPT) from C. jingzhao for the first time. CPT remarkably alleviated formalin-induced inflammatory pain and significantly inhibited inflammatory responses. In vivo, CPT attenuated neutrophil infiltration and plantar tissue edema and suppressed the mRNA expression of pro-inflammatory molecules. In vitro, CPT suppressed inflammation triggered by lipopolysaccharide (LPS) in both RAW 264.7 and iBMDM cells, reducing expressions of inducible nitric oxide synthase (iNOS), superoxide, and pro-inflammatory molecules. A mechanistic study revealed that CPT exerted an anti-inflammatory activity by blocking the mitogen-activated protein kinases (MAPK) and nuclear factor-kappa B (NF-κB) signaling pathways, as well as alleviating the ubiquitination of tumor necrosis factor receptor-associated factor 6 (TRAF6). Our results elucidated the pharmacodynamic material basis of C. jingzhao, and CPT can be a promising lead for alleviating inflammation and inflammatory pain.
A process is disclosed for determining the concentration of an unbound species, e.g., thyroxine, cortisol, testosterone, or digoxin, in a liquid sample containing the species and protein. The sample is incubated with antibody specific to the species to be detected and a distinguishable analogue of the species, the antibody being initially separated from the sample by semipermeable membrane capable of excluding the passage of natural protein and antibody but allowing passage of the species and its analogue. The antibody and analogue are contained in semipermeable microcapsules. Free species in the sample permeates the membranes and competes for sites of attachment to the antibody with the analogue. The antibody is then separated from residual unbound species and unbound analogue. The amount of analogue present either in association with the antibody or in the remainder of the reaction system is indicative of the level of unbound species originally present in the sample.
We studied the effects of rheumatoid arthritis (RA) autoantibodies that target malondialdehyde-acetaldehyde protein adducts (anti-MAA) on inflammation and macrophage functions. We detected a profound reprogramming of gene expressions and the production of chemokines, such as CCL22 and CCL24, in anti-MAA exposed macrophages. Moreover, anti-MAA pretreatment promoted a more inflammatory cytokine profile upon TLR activation. Although anti-MAA are typically multi-reactive, we observed a prominent clonal diversity in inducing macrophage activation. Anti-MAA antibodies were not arthritogenic in mice, but altered a set of cytokine and growth factor encoding genes in the joints. In individuals at risk of RA anti-MAA IgG levels correlated with circulating inflammatory mediators prior to and at arthritis onset. Certain IgG anti-MAA clones may thus contribute to an inflammatory priming of the joint prior to the onset of systemic inflammation via inducing FcγR-mediated macrophage pre-activation and setting the stage for augmented responses to subsequent inflammatory stimuli.
A porous implantable oral prosthesis which can be used to replicate and replace any hard tissue portion of the mouth such as bone and teeth is described. The prosthesis comprises sintered polymeric particles coated with a hydrophilic material. The polymeric particles vary in size so as to provide an area of relatively coarse porosity where the prosthesis is intended to interface with bone tissue and relatively fine porosity where it is intended to interface with soft tissue. A process for producing such prosthesis by filling a mold with appropriate molding compounds comprised of polymeric particles and a hydrophilic monomer, sintering the particles and polymerizing the monomer by dielectric heating, removing the sintered material from the cooled mold, and placing the prosthesis in a hot liquid to remove residues is described. An entire tooth, including a nonporous crown may be produced. A process for producing a porous replica of a tooth root suitable for implantation immediately after extraction of a tooth is disclosed. When extraction has taken place in the past and has resulted in the bone and gum receding, a porous implant inserted in a newly drilled hole in the patient's jaw bone may be used. A central post associated with the implant projecting above the gum may be used for attaching a denture, partial bridge or a crown. A porous implant may be used for jaw bone replacement in order to improve the fitting of dentures.
The invention discloses a traditional Chinese medicine oral liquid for treating woman leukorrhagia. When woman lower energizer is invaded by damp-heat pathogen, a lot of leucorrhea will be excreted to trigger human body discomfort. The oral liquid is prepared from fresh saururus chinensis and fresh mallotus paniculatus through the following steps: (1) soaking fresh saururus chinensis and fresh mallotus paniculatus in water with a volume which is 3 to 5 times the volume of the raw materials, for 30 to 60 minutes, heating to 100 DEG C, extracting for 60 to 120 minutes, extracting for another time, emerging the two extracts, filtering the emerged extract so as to obtain a filtrate, condensing the filtrate until the relative density of the condensed filtrate reaches 1.15 to 1.20 when the filtrate is measured at a temperature of 60 DEG C so as to obtain a condensed liquid for later use; (2) adding water into the condensed liquid, heating until the water starts to boil, blending to control that each milliliter of liquid contains 3 to 5 grams of drugs, and finally packaging so as to obtain the oral liquid. The traditional Chinese medicine oral liquid has the functions of clearing heat, moistening dryness, removing dampness, and inducing astringency; and can be used to treat leukorrhagia caused by dampness-heat. The oral liquid is orally taken, three times a day, and 30 to 50 milliliters for each time. The clinical effect of the oral liquid is good, the effective rate can reach 100%, no local or systemic adverse reaction appears during the medication period, and thus the oral liquid is safe.
A dietary fiber composition including a water-soluble fiber and a water-insoluble protein is provided. The water-insoluble protein provides an enteric-like coating for the water-soluble fiber without affecting the beneficial properties of the fiber. A process for preparing the composition and a method of use are also provided. A dietary fiber composition including a water-soluble fiber, a water-insoluble protein and an acidulant is provided. The dietary fiber composition can be used to preserve dehydrated or fresh fruits and vegetables by applying an aqueous solution of the composition to the produce.  Alternatively, a solution of the dietary fiber composition can be frozen and the ice including the dietary fiber composition can be used to chill freshly caught fish or meat.
Participants will receive nemtrabrutinib oral tablets at specified doses daily starting at Cycle 1 Day 1 (C1D1) and venetoclax oral tablets at doses of 20 mg up to 400 mg daily starting at Cycle 2 Day 1 (C2D1) up to 2 years post C2D1 or until progressive disease (PD) or discontinuation. A cycle = 4 weeks.
Patients receive radiolabeled technetium Tc 99m sulfur colloid injected around the tumor 6 hours prior to or after induction of anesthesia right before surgery. Patients then undergo radical hysterectomy and complete pelvic and low para-aortic lymphadenectomy. Intraoperatively, patients undergo lymphatic mapping and sentinel lymph node identification using isosulfan blue or methylene blue injected at 4 locations in the cervix and a hand-held gamma counter.
This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
This is an open label, multi-center Phase 2 study. Approximately 40 patients will be enrolled in a single study arm. RhLF, at a dose of 1.5 g \[1 vial\], twice a day (b.i.d.), will be administered orally for two cycles each of 12 consecutive weeks followed by 2 weeks off. A maximum of two additional cycles may be given if an objective response is obtained or if the patient has stable disease and no increase in the size of the target tumor(s) relative to either the Screening CT or the most recent CT measurement, measured according to RECIST prior to the additional cycle(s). Response and progression-free survival will be evaluated for the first 20 patients enrolled. If no patient has an objective response and less than 10% of the patients are alive and progression-free at 14 weeks from the start of Study Drug, then the study will be terminated. If in either Cycle 3 or Cycle 4, more than three out of the first ten patients or more than six out of the first twenty patients entering the cycle experience a Grade 3 or 4 Study-Drug-related adverse event, no further patients will advance into Cycle 3 or Cycle 4.
The skin external use composition contains 0.1% by mass to 8% by mass of a nonemulsifying silicone elastomer, a polyether modified silicone surfactant and a hydrophilic nonionic surfactant. The hydrophilic nonionic surfactant includes a glycerin derivative type surfactant. The polyether modified silicone surfactant is 0.3 parts by mass or more relative to 1 part by mass of the silicone elastomer. The hydrophilic nonionic surfactant is at least 0.2 part by mass relative to 1 part by mass of the silicone elastomer. In the case of containing an amphoteric surfactant, the amphoteric surfactant is 1.5 parts by mass or less relative to 1 part by mass of the glycerin derivative type surfactant. The viscosity of the composition is 9,500 mPa,s or less.
Pediatric transfusion is a complex area of medicine covering a wide age range, from neonates to young adults. Compared to adult practice, there is a relative lack of high-quality research to inform evidence-based guidelines. We aimed to adapt the pre-existing high-quality practice guidelines for the transfusion of blood components in different pediatric age groups to be available for national use by general practitioners, pediatricians, and other health care professionals. The guideline panel included 17 key leaders from different Egyptian institutions. The panel used the Adapted ADAPTE methodology. The panel prioritized the health questions and recommendations according to their importance for clinicians and patients. The procedure included searching for existing guidelines, quality appraisal, and adaptation of the recommendations to the target context of use. The guideline covered all important aspects of the indications, dosing, and administration of packed red cells, platelets, and fresh frozen plasma. It also included transfusion in special situations, e.g., chronic hemolytic anemia and aplastic anemia, management of massive blood loss, malignancies, surgery, recommendations for safe transfusion practices, and recommendations for modifications of cellular blood components. The final version of the adapted clinical practice guideline (CPG) has been made after a thorough review by an external review panel and was guided by their official recommendations and modifications. A set of implementation tools included algorithms, tables, and flow charts to aid decision-making in practice. This adapted guideline serves as a tool for safe transfusion practices in different pediatric age groups.
The present invention relates to a synthetic ginseng saponin complex and a method for preparing the same. Ginseng contains various types of ginsenosides as saponin the ginseng originally possesses is decomposed or converted according to physicochemical and biological treatment. Powders of white ginseng, red ginseng, Taegeuk ginseng (taekuksam), black ginseng, fermented red ginseng, and wild ginseng cultured roots, which are representative processed ginseng according to ginseng processing schemes, are prepared, and mixed in a specific ratio. Accordingly, all of various ginsenoside ingredients produced differently according to each processing scheme are included in the complex of the present invention. A ginseng multi-saponin complex "GINOS" according to the present invention has excellent efficacy in improving free radical scavenging ability, increasing reducing power, inhibiting NO and ROS production, enhancing immunity, and inhibiting tyrosinase activity. Also, the complex has an advantage of enabling to consume all the ginsenosides of different types of processed ginseng at once. The ginseng multi-saponin complex according to the present invention can be used as a raw material for foods, health functional foods, cosmetics, and pharmaceuticals with improved representative effects of ginseng, such as anti-oxidation, anti-inflammation, skin whitening, and immunity enhancement.